ANTHRACYCLINE-INDUCED CARDIO-AND VASO-TOXICITY IN PATIENTS RECEIVING CHEMOTHERAPY FOR BREAST CANCER

Evangelos Oikonomou(National and Kapodistrian University of Athens), Dimitris Tousoulis(National and Kapodistrian University of Athens), Alexios S. Antonopoulos(National and Kapodistrian University of Athens), George-Angelo Papamikroulis(National and Kapodistrian University of Athens), Gerasimos Siasos(Brigham and Women's Hospital), Μaria Anastasiou(National and Kapodistrian University of Athens), Aristotelis Bamias(National and Kapodistrian University of Athens), Flora Zagouri(National and Kapodistrian University of Athens), Θεοδώρα Ψαλτοπούλου(Alexandra Hospital), Athina Goliopoulou(National and Kapodistrian University of Athens), Sotirios Tsalamandris(Hippocration General Hospital), Vasiliki Tsigkou(National and Kapodistrian University of Athens)
Journal of the American College of Cardiology
March 1, 2018
10.1016/s0735-1097(18)32624-x
Cited by 1

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data
|The Lancet|2018|1.1k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-Year Follow-Up Outcomes and Differences Across Regions
|European Journal of Heart Failure|2016|781